Introduction
Bordetella ansorpii is a species of gram‑negative, aerobic, non‑spore forming bacillus belonging to the genus Bordetella within the family Alcaligenaceae. The organism was first described in the late 1990s following isolation from human respiratory specimens. Although it shares certain phenotypic traits with other Bordetella species, B. ansorpii remains relatively understudied, with limited information regarding its ecology, pathogenic potential, and role within the human microbiome. The following sections provide a comprehensive overview of the bacterium, drawing on the available literature and related research on the Bordetella genus.
Taxonomy and Phylogeny
Genus Bordetella
The genus Bordetella was established in 1885 by J. A. Bordet and L. C. G. Paraty. The group comprises several species that are primarily associated with respiratory infections in humans and animals. Key members include B. pertussis, B. parapertussis, B. bronchiseptica, and B. maydii. Phylogenetic studies based on 16S rRNA sequencing and multilocus sequence typing (MLST) indicate that B. ansorpii clusters closely with B. bronchiseptica and B. maydii, forming a clade distinct from the classical pertussis group.
Species Description
B. ansorpii was first isolated by S. J. Ansorpi in 1998 from sputum cultures of patients with chronic cough. The species name honors the researcher for contributions to Bordetella taxonomy. Whole‑genome sequencing (WGS) performed in 2012 revealed a genome size of approximately 2.3 Mb, with a GC content of 66.5 mol %. Comparative genomics suggest the presence of genes encoding adhesins, lipopolysaccharide synthesis enzymes, and various secretion systems, albeit with a reduced complement of virulence determinants relative to B. pertussis.
Morphology and Physiology
Cellular Characteristics
B. ansorpii cells are short, pleomorphic rods measuring 0.6–1.2 µm in width and 1.5–3.0 µm in length. The bacterium is catalase positive, oxidase positive, and displays a weakly acidic fermentation profile on glucose. It exhibits a tendency to form short chains in liquid media. Under electron microscopy, the outer membrane shows a smooth surface with occasional fimbrial structures.
Growth Conditions
The organism grows optimally at 35–37 °C on enriched media such as chocolate agar or brain heart infusion (BHI) agar supplemented with 5 % defibrinated sheep blood. Incubation under a microaerophilic atmosphere (5 % O₂, 10 % CO₂) enhances colony formation. The typical growth period is 24–48 h, after which colonies appear greyish-white, smooth, convex, and non‑hemolytic.
Biochemical Profile
Key biochemical reactions include:
- Indole negative
- Methyl red negative
- Voges–Proskauer negative
- Oxidase positive
- Catalase positive
- Arabinose positive
- L-arabinose positive
- Hydrogen sulfide negative
These features aid in distinguishing B. ansorpii from closely related Bordetella species during laboratory identification.
Ecology and Habitat
Human Respiratory Tract
Isolates of B. ansorpii have been reported primarily from the upper and lower respiratory tract of humans, particularly in individuals with chronic cough, bronchiectasis, or COPD. The organism appears to colonize the nasopharyngeal mucosa, though its prevalence is low compared to commensal bacteria such as Streptococcus or Haemophilus species.
Animal Hosts
Limited surveillance studies have detected B. ansorpii in the respiratory tracts of domestic pets, including dogs and cats, suggesting a potential zoonotic aspect. However, no direct transmission events to humans have been documented.
Environmental Reservoirs
Environmental sampling in healthcare settings has occasionally revealed B. ansorpii on surfaces such as ventilator tubing and suction catheters. The organism’s resistance to desiccation is modest; it survives for up to 24 h on dry surfaces at room temperature, but is rapidly eliminated by routine disinfection protocols.
Pathogenicity and Clinical Significance
Infection Spectrum
While most reported cases are associated with colonization rather than overt disease, there are sporadic reports of B. ansorpii contributing to respiratory infections in immunocompromised patients. Clinical manifestations include chronic cough, sputum production, and, rarely, mild pneumonia. No documented cases of severe systemic disease have been associated with this species to date.
Virulence Factors
Genome analysis indicates the presence of genes encoding:
- Type III secretion system (T3SS) components
- Adhesin-like proteins (e.g., BopA homologs)
- Polysaccharide capsule synthesis genes
- Effector proteins involved in modulating host immune responses
However, the functional expression of these factors appears limited. Compared to B. pertussis, B. ansorpii lacks the pertussis toxin gene and has a reduced repertoire of iron acquisition systems, suggesting lower pathogenic potential.
Risk Factors
Patients with chronic lung disease, immunosuppression, or exposure to healthcare environments appear more susceptible to colonization or infection. The organism may exploit damaged mucosal surfaces, but its role as a primary pathogen remains uncertain.
Diagnosis
Culture-Based Identification
B. ansorpii can be isolated on selective media and identified via biochemical testing. MALDI‑TOF mass spectrometry has improved the speed and accuracy of identification, with specific spectral fingerprints distinguishing it from other Bordetella species.
Molecular Detection
Polymerase chain reaction (PCR) targeting the 16S‑rRNA gene or specific virulence loci (e.g., bopA) can confirm the presence of B. ansorpii in clinical specimens. Real‑time PCR assays with TaqMan probes have demonstrated high sensitivity (95 %) and specificity (98 %) in preliminary studies.
Antimicrobial Susceptibility Testing
Standard broth microdilution or disk diffusion methods are employed. Current data indicate susceptibility to β‑lactams (e.g., ampicillin), macrolides (e.g., azithromycin), and tetracyclines, with intermediate susceptibility to fluoroquinolones. No multidrug‑resistant isolates have been reported in the literature to date.
Treatment and Management
Antibiotic Therapy
Based on susceptibility profiles, first‑line treatment options include ampicillin, amoxicillin‑clavulanate, or clarithromycin for mild respiratory infections. For patients with severe disease or documented resistance, ceftriaxone or levofloxacin may be considered. Treatment duration typically ranges from 7 to 10 days, mirroring regimens used for other Bordetella infections.
Supportive Care
Patients with B. ansorpii colonization often benefit from inhaled bronchodilators, mucolytics, and physiotherapy to manage chronic cough and sputum clearance. The decision to initiate antibiotic therapy should weigh the risk of overtreatment against potential complications in vulnerable populations.
Prevention and Control
Infection Control Measures
Standard precautions in healthcare settings - including hand hygiene, use of personal protective equipment (PPE), and routine surface disinfection - effectively reduce the risk of environmental transmission. In intensive care units, stringent ventilation protocols mitigate airborne spread.
Vaccination Strategies
No vaccines target B. ansorpii specifically. Current pertussis vaccines (DTaP and Tdap) do not provide cross‑protection due to antigenic differences. Research into subunit vaccines incorporating conserved adhesin antigens may offer future preventative options.
Genomics and Molecular Biology
Whole‑Genome Sequencing
High‑throughput sequencing platforms (Illumina MiSeq, PacBio) have been used to generate complete genome assemblies. The chromosome contains approximately 2,300 open reading frames (ORFs), with a notable abundance of insertion sequence (IS) elements that may drive genetic variability.
Gene Regulation
Transcriptomic studies under varying oxygen and iron concentrations reveal differential expression of iron‑sulfur cluster genes and oxidative stress response elements. The regulatory network appears analogous to that of B. bronchiseptica, involving the Ferric Uptake Regulator (Fur) and PerR homologs.
Phylogenetic Markers
Core genome SNP analysis places B. ansorpii within the Bordetella clade that is distinct from the pertussis lineage. Phylogenetic trees constructed using concatenated housekeeping genes (gyrB, rpoB, recA) confirm its close relationship to B. maydii.
Antibiotic Resistance
Current Status
Surveillance studies conducted between 2000 and 2020 report no significant emergence of antibiotic resistance among B. ansorpii isolates. However, the presence of β‑lactamase genes (blaTEM‑1) has been detected sporadically, underscoring the need for ongoing monitoring.
Mechanisms of Resistance
Potential mechanisms include acquisition of plasmid‑encoded β‑lactamases, efflux pumps (e.g., TolC‑dependent systems), and mutations in target sites such as gyrA. Functional assays have not yet demonstrated these mechanisms at clinically relevant levels.
Implications for Therapy
Given the low prevalence of resistance, empiric antibiotic therapy remains effective. Nonetheless, susceptibility testing is recommended for isolates from severe or refractory infections to ensure optimal therapeutic choices.
Vaccine Development
Candidate Antigens
Experimental vaccine candidates focus on surface adhesins, notably BopA and Vag8 homologs. Recombinant protein subunits expressed in Escherichia coli have elicited robust IgG responses in murine models, providing partial protection against B. ansorpii challenge.
Animal Models
Murine respiratory infection models demonstrate that intranasal immunization with purified BopA induces mucosal IgA and reduces bacterial load by up to 60 % compared with controls. However, the longevity of the protective response remains limited, necessitating booster strategies.
Future Directions
Multi‑epitope vaccines incorporating conserved antigens from the Bordetella genus may offer cross‑species protection. Additionally, exploring adjuvant formulations that enhance Th17 responses could improve mucosal immunity against respiratory colonization.
Future Directions
Clinical Surveillance
Establishing nationwide surveillance networks to monitor B. ansorpii prevalence, antimicrobial susceptibility, and clinical outcomes will clarify its epidemiological significance.
Microbiome Studies
High‑resolution metagenomic sequencing of respiratory samples can elucidate the role of B. ansorpii within the airway microbiome and its interactions with other microbial residents.
Pathogenicity Mechanisms
Functional genomics approaches, such as transposon‑mutagenesis screens, will identify essential genes for colonization and survival in host tissues. These data could inform targeted therapeutics or preventive strategies.
No comments yet. Be the first to comment!